Karl Walter Bock
Research Subjects
Karl Walter Bock has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Christoph Köhle
9 shared publicationsBarbara S Bock-Hennig
3 shared publicationsHarald Gschaidmeier
Institute of Toxicology, University of Tübingen, Wilhelmstraße 56, D-72074 Tübingen, Germany
3 shared publicationsAchim Orzechowski
1 shared publicationAlbrecht Seidel
Institute of Toxicology, University of Tübingen, D-72074 Tübingen, Germany
1 shared publicationAndrew D Grove
Institute of Toxicology, University of Tübingen, D-72074 Tübingen, Germany
1 shared publication
Latest Publications
- Open Access
- 11 December 2024
- Published by Frontiers Media SA in Frontiers in Toxicology
- Vol. 6, 1491184
Ah receptor, vitamin B12 and itaconate: how localized decrease of vitamin B12 prevents survival of macrophage-ingested bacteria
Ah receptor (AHR) is a ligand-dependent transcription factor and environmental sensor (1,2). The receptor has been discovered in studies of toxicity of the persistent AHR ligand TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) leading to deregulation of the receptor. Recently, a number of physiological receptor functions have been identified. One of its multiple physiological functions is involved in intestinal barrier integrity and host-microbiome interaction (3,4). The microbiome of human colon includes anaerobic archaea and bacteria generating vitamin B12 (5,6). Surprisingly, vitamin B12 has been recently identified as natural AHR antagonist (7). This important finding appears to be unrecognized by many scientists in the AHR field. A previous minireview (8) and the present opinion on links between Ah receptor, vitamin B12 and itaconate are intended to stimulate the interest in the unsolved finding that vitamin B12 is a direct antagonist of the AHR.Both vitamin B12 and folic acid have been identified as natural antagonists of the ligand-modulated AHR (7). Indead, the two vitamins directly bind to the receptor in the cytosol, blocking AHR's nuclear translocation and transcriptional signaling. In this way, they possibly compete with many environmental toxic ligands such as TCDD, dietary phytochemicals and microbial products including indoles and pigmented virulence factors (9). Vitamin B12 and folic acid are known to be cofactors of the enzyme methionine synthase in the one-carbon cycle facilitating the de novo synthesis of nucleotides and methylation of DNA and protein (10). Here, the focus is on B12-dependent methylmalonyl-CoA mutase (MUT) that is involved in lipid metabolism, particularly in converting propionyl-CoA to the TCA cycle metabolite succinyl-CoA. However, the second vitamin B12-dependent enzyme, methionine synthase, should not be neglected in studies of possible links between AHR and vitamin B12, as discussed in section 3.It has been demonstrated that macrophages activated by microbial pathogenassociated molecular patterns and cytokines upregulate expression of the enzyme cis-aconitate decarboxylase (CAD), also termed ACOD1 and Irg1, generating the antimicrobial and antiinflammatory itaconate (11,12). CAD is induced by the key antioxidant regulator Nrf2 (13) and by AHR since Nrf2 has been demonstrated to operate in mutual crosstalk with the AHR (14,15). Increased itaconate levels in mitochondria lead to toxic itaconyl-CoA that has been demonstrated to form a stable biradical when bound to the enzyme MUT leading to decreased vitamin B12 (16,17).The toxic reaction of itaconyl-CoA with MUT is supported by studies of TCDD-treated mice. These studies demonstrated that B12-dependent MUT activity is inhibited in mitochondria, leading to decreased vitamin B12 serum thereby redirecting propionyl-CoA metabolism to an alternative ß-oxidation-like pathway resulting in acrylyl-CoA conjugate buildup leading to non-alcoholic fatty liver (NAFLD) (18).Importantly, decreased B12 levels in macrophages also inhibit survival of macrophage-ingested bacteria (figure 1) (19). This inhibition is necessary since bacteria such as M. tuberculosis managed to degrade itaconate (20). Macrophages may temporarily tolerate a localized decrease of B12.As mentioned in the introduction, AHR is involved in intestinal barrier integrity and host-microbiome interaction (3). In particular, AHR signalling is required for the resolution of injury-induced colonic stem cells (21). In this context it is interesting that vitamin B12 is a limiting factor for induced cellular plasticity and tissue repair. In the dextran sulfate sodium model of acute ulcerative colitis serum vitamin B12 was observed to be depleted and vitamin B12 supplementation enhanced specific markers of epigenetic histone methylation (22). Hence, there are links between AHR and vitamin B12 signaling in the intestine.It is understood that both AHR and vitamin B12 are involved in complex, tissuedependent signalling networks. Tissue-dependent links between AHR and the two vitamin B12-dependet enzymes, methylmalonyl-CoA mutase (MUT) and methionine synthase have been discussed here. Notably, persistent AHR activation has to be avoided since it may lead to toxicity and cancer. In studies using a constitutivelyactive AHR mutant it has been demonstrated that the gastric mucosa is particularly affected (23). Interestingly, the gastric pump inhibitor omeprazole has been identified as AHR agonist (24). The discussed opinion deals with tissue-dependent links between AHR, vitamin B12 and itaconate, for example, with findings how the decrease of vitamin B12 leads to death of macrophage-ingested bacteria. It is hoped the discussion may stimulate the interest of AHR scientists in attempts to substantiate and understand the surprising finding that vitamin B12 is a direct antagonist of the AHR (7).
- 11 December 2024
- Published by Frontiers Media SA in Frontiers in Toxicology
- Vol. 6, 1491184
Open AccessAh receptor, vitamin B12 and itaconate: how localized decrease of vitamin B12 prevents survival of macrophage-ingested bacteria
Ah receptor (AHR) is a ligand-dependent transcription factor and environmental sensor (1,2). The receptor has been discovered in studies of toxicity of the persistent AHR ligand TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) leading to deregulation of the receptor. Recently, a number of physiological receptor functions have been identified. One of its multiple physiological functions is involved in intestinal barrier integrity and host-microbiome interaction (3,4). The microbiome of human colon includes anaerobic archaea and bacteria generating vitamin B12 (5,6). Surprisingly, vitamin B12 has been recently identified as natural AHR antagonist (7). This important finding appears to be unrecognized by many scientists in the AHR field. A previous minireview (8) and the present opinion on links between Ah receptor, vitamin B12 and itaconate are intended to stimulate the interest in the unsolved finding that vitamin B12 is a direct antagonist of the AHR.Both vitamin B12 and folic acid have been identified as natural antagonists of the ligand-modulated AHR (7). Indead, the two vitamins directly bind to the receptor in the cytosol, blocking AHR's nuclear translocation and transcriptional signaling. In this way, they possibly compete with many environmental toxic ligands such as TCDD, dietary phytochemicals and microbial products including indoles and pigmented virulence factors (9). Vitamin B12 and folic acid are known to be cofactors of the enzyme methionine synthase in the one-carbon cycle facilitating the de novo synthesis of nucleotides and methylation of DNA and protein (10). Here, the focus is on B12-dependent methylmalonyl-CoA mutase (MUT) that is involved in lipid metabolism, particularly in converting propionyl-CoA to the TCA cycle metabolite succinyl-CoA. However, the second vitamin B12-dependent enzyme, methionine synthase, should not be neglected in studies of possible links between AHR and vitamin B12, as discussed in section 3.It has been demonstrated that macrophages activated by microbial pathogenassociated molecular patterns and cytokines upregulate expression of the enzyme cis-aconitate decarboxylase (CAD), also termed ACOD1 and Irg1, generating the antimicrobial and antiinflammatory itaconate (11,12). CAD is induced by the key antioxidant regulator Nrf2 (13) and by AHR since Nrf2 has been demonstrated to operate in mutual crosstalk with the AHR (14,15). Increased itaconate levels in mitochondria lead to toxic itaconyl-CoA that has been demonstrated to form a stable biradical when bound to the enzyme MUT leading to decreased vitamin B12 (16,17).The toxic reaction of itaconyl-CoA with MUT is supported by studies of TCDD-treated mice. These studies demonstrated that B12-dependent MUT activity is inhibited in mitochondria, leading to decreased vitamin B12 serum thereby redirecting propionyl-CoA metabolism to an alternative ß-oxidation-like pathway resulting in acrylyl-CoA conjugate buildup leading to non-alcoholic fatty liver (NAFLD) (18).Importantly, decreased B12 levels in macrophages also inhibit survival of macrophage-ingested bacteria (figure 1) (19). This inhibition is necessary since bacteria such as M. tuberculosis managed to degrade itaconate (20). Macrophages may temporarily tolerate a localized decrease of B12.As mentioned in the introduction, AHR is involved in intestinal barrier integrity and host-microbiome interaction (3). In particular, AHR signalling is required for the resolution of injury-induced colonic stem cells (21). In this context it is interesting that vitamin B12 is a limiting factor for induced cellular plasticity and tissue repair. In the dextran sulfate sodium model of acute ulcerative colitis serum vitamin B12 was observed to be depleted and vitamin B12 supplementation enhanced specific markers of epigenetic histone methylation (22). Hence, there are links between AHR and vitamin B12 signaling in the intestine.It is understood that both AHR and vitamin B12 are involved in complex, tissuedependent signalling networks. Tissue-dependent links between AHR and the two vitamin B12-dependet enzymes, methylmalonyl-CoA mutase (MUT) and methionine synthase have been discussed here. Notably, persistent AHR activation has to be avoided since it may lead to toxicity and cancer. In studies using a constitutivelyactive AHR mutant it has been demonstrated that the gastric mucosa is particularly affected (23). Interestingly, the gastric pump inhibitor omeprazole has been identified as AHR agonist (24). The discussed opinion deals with tissue-dependent links between AHR, vitamin B12 and itaconate, for example, with findings how the decrease of vitamin B12 leads to death of macrophage-ingested bacteria. It is hoped the discussion may stimulate the interest of AHR scientists in attempts to substantiate and understand the surprising finding that vitamin B12 is a direct antagonist of the AHR (7).
- 17 June 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 214, 115658
Aryl hydrocarbon receptor (AHR): Towards understanding intestinal microbial ligands including vitamin B12 and folic acid as natural antagonists
- 17 June 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 214, 115658
Aryl hydrocarbon receptor (AHR): Towards understanding intestinal microbial ligands including vitamin B12 and folic acid as natural antagonists
- Open Access
- 24 September 2021
- Published by Springer Nature in Archives of Toxicology
- Vol. 95 (11) , 3449-3458
Aryl hydrocarbon receptor (AHR) functions in infectious and sterile inflammation and NAD+-dependent metabolic adaptation
Aryl hydrocarbon receptor (AHR) research has shifted from exploring dioxin toxicity to elucidation of various physiologic AHR functions. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is known to exert cellular stress-mediated sterile inflammatory responses in exposed human tissues but may be lethal in sensitive species. Inflammation can be thought of as the extreme end of a spectrum ranging from homeostasis to stress responses (sterile inflammation) and to defense against infection (infectious inflammation). Defense against bacterial infection by generation of reactive oxygen species has to be strictly controlled and may use up a considerable amount of energy. NAD+-mediated energy metabolism adapts to various inflammatory responses. As examples, the present commentary tries to integrate responses of AHR and NAD+-consuming enzymes (PARP7/TiPARP, CD38 and sirtuins) into infectious and stress-induced inflammatory responses, the latter exemplified by nonalcoholic fatty liver disease (NAFLD). TCDD toxicity models in sensitive species provide hints to molecular AHR targets of energy metabolism including gluconeogenesis and glycolysis. AHR research remains challenging and promising.
- 24 September 2021
- Published by Springer Nature in Archives of Toxicology
- Vol. 95 (11) , 3449-3458
Open AccessAryl hydrocarbon receptor (AHR) functions in infectious and sterile inflammation and NAD+-dependent metabolic adaptation
Aryl hydrocarbon receptor (AHR) research has shifted from exploring dioxin toxicity to elucidation of various physiologic AHR functions. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is known to exert cellular stress-mediated sterile inflammatory responses in exposed human tissues but may be lethal in sensitive species. Inflammation can be thought of as the extreme end of a spectrum ranging from homeostasis to stress responses (sterile inflammation) and to defense against infection (infectious inflammation). Defense against bacterial infection by generation of reactive oxygen species has to be strictly controlled and may use up a considerable amount of energy. NAD+-mediated energy metabolism adapts to various inflammatory responses. As examples, the present commentary tries to integrate responses of AHR and NAD+-consuming enzymes (PARP7/TiPARP, CD38 and sirtuins) into infectious and stress-induced inflammatory responses, the latter exemplified by nonalcoholic fatty liver disease (NAFLD). TCDD toxicity models in sensitive species provide hints to molecular AHR targets of energy metabolism including gluconeogenesis and glycolysis. AHR research remains challenging and promising.
- 1 February 2021
- Published by Elsevier in Biochemical Pharmacology
- Vol. 184, 114346
Aryl hydrocarbon receptor (AHR), integrating energy metabolism and microbial or obesity-mediated inflammation
- 1 February 2021
- Published by Elsevier in Biochemical Pharmacology
- Vol. 184, 114346
Aryl hydrocarbon receptor (AHR), integrating energy metabolism and microbial or obesity-mediated inflammation
- 1 December 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 182, 114220
Aryl hydrocarbon receptor (AHR)-mediated inflammation and resolution: Non-genomic and genomic signaling
- 1 December 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 182, 114220
Aryl hydrocarbon receptor (AHR)-mediated inflammation and resolution: Non-genomic and genomic signaling
- 1 August 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 178, 114093
Aryl hydrocarbon receptor (AHR) functions: Balancing opposing processes including inflammatory reactions
- 1 August 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 178, 114093
Aryl hydrocarbon receptor (AHR) functions: Balancing opposing processes including inflammatory reactions
- 1 November 2019
- Published by Elsevier in Biochemical Pharmacology
- Vol. 169, 113620
Functions of aryl hydrocarbon receptor (AHR) and CD38 in NAD metabolism and nonalcoholic steatohepatitis (NASH)
- 1 November 2019
- Published by Elsevier in Biochemical Pharmacology
- Vol. 169, 113620
Functions of aryl hydrocarbon receptor (AHR) and CD38 in NAD metabolism and nonalcoholic steatohepatitis (NASH)
- 1 October 2019
- Published by Elsevier in Biochemical Pharmacology
- Vol. 168, 65-70
Aryl hydrocarbon receptor (AHR): From selected human target genes and crosstalk with transcription factors to multiple AHR functions
- 1 October 2019
- Published by Elsevier in Biochemical Pharmacology
- Vol. 168, 65-70
Aryl hydrocarbon receptor (AHR): From selected human target genes and crosstalk with transcription factors to multiple AHR functions
- 16 February 2019
- Published by Elsevier in Biochemical Pharmacology
- Vol. 163, 128-132
Aryl hydrocarbon receptor (AHR) functions in NAD+ metabolism, myelopoiesis and obesity
- 16 February 2019
- Published by Elsevier in Biochemical Pharmacology
- Vol. 163, 128-132
Aryl hydrocarbon receptor (AHR) functions in NAD+ metabolism, myelopoiesis and obesity